Received: from GV2PR02MB11348.eurprd02.prod.outlook.com (2603:10a6:150:2b2::19) by DB9PR02MB7817.eurprd02.prod.outlook.com with HTTPS; Fri, 26 Jun 2026 09:16:24 +0000 Received: from GVXPR02MB12202.eurprd02.prod.outlook.com (2603:10a6:150:318::18) by GV2PR02MB11348.eurprd02.prod.outlook.com (2603:10a6:150:2b2::19) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.21.159.15; Fri, 26 Jun 2026 09:16:17 +0000 Received: from GVXPR02MB12202.eurprd02.prod.outlook.com ([fe80::7e68:6b0b:67d4:d05f]) by GVXPR02MB12202.eurprd02.prod.outlook.com ([fe80::7e68:6b0b:67d4:d05f%2]) with mapi id 15.21.0159.015; Fri, 26 Jun 2026 09:16:16 +0000 From: "Andrus Varki - RA" To: "Info - SOM" Cc: "Mari Amos - SOM" , =?utf-8?Q?K=C3=A4rolin_Jenas_-_RA?= References: <0b1142f2de5b4ee9b77a206ee9671966@ravimiamet.ee> In-Reply-To: Subject: =?utf-8?Q?Ed:_Eeln=C3=B5u_edastamine_koosk=C3=B5last?= =?utf-8?Q?amiseks_ja_arvamuse_avaldamiseks?= Date: Fri, 26 Jun 2026 12:16:16 +0300 Keywords: Mall Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_002F_01DD072E.90C088D0" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQIOkpl4/ke9+WNmGnvinYgaN9pG2wEidV1AAvAO1mEBgZBMcAI+CNbTAO+NVD0CDMzEsQJQEHqM Authentication-Results: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; X-MS-Exchange-Organization-ExpirationStartTime: 26 Jun 2026 09:16:17.1027 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-MS-Exchange-Organization-Network-Message-Id: 185566c9-77c6-4960-eef1-08ded36393c6 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-PublicTrafficType: Email X-MS-TrafficTypeDiagnostic: GVXPR02MB12202:EE_|GV2PR02MB11348:EE_|DB9PR02MB7817:EE_ X-MS-Exchange-Organization-AuthSource: GVXPR02MB12202.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Internal X-MS-Office365-Filtering-Correlation-Id: 185566c9-77c6-4960-eef1-08ded36393c6 X-MS-Exchange-AtpMessageProperties: SA X-MS-Exchange-Organization-SCL: 1 X-Microsoft-Antispam: BCL:0;ARA:13230040|23010399003|31052699007|39142699007|366016|55112099003|56012099006|11063799006|8096899003|4143699003|22082099003|13003099007|18002099003|41050700001; X-Forefront-Antispam-Report: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GVXPR02MB12202.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(23010399003)(31052699007)(39142699007)(366016)(55112099003)(56012099006)(11063799006)(8096899003)(4143699003)(22082099003)(13003099007)(18002099003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 26 Jun 2026 09:16:16.7427 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: 185566c9-77c6-4960-eef1-08ded36393c6 X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-AuthSource: GVXPR02MB12202.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-FromEntityHeader: Hosted X-MS-Exchange-Transport-CrossTenantHeadersStamped: GV2PR02MB11348 X-MS-Exchange-Transport-EndToEndLatency: 00:00:08.0870514 X-MS-Exchange-Processed-By-BccFoldering: 15.21.0159.007 X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 Content-Language: et x-ms-exchange-organization-originalclientipaddress: 45.156.32.7 x-ms-exchange-organization-originalserveripaddress: 2603:10a6:150:318::18 X-OlkEid: 00000000D07AAE8E23CDBE4CA04D01CCD82FCB7E070034AD76187591974DBF6C4F76951C873A01000200000000005797C783AAECB34FA6C879FF487E64D9000000000DA8000015B2E58335761048AE497F91B08958A0 X-MS-Has-Attach: X-MS-TNEF-Correlator: acceptlanguage: et-EE, en-US x-codetwoprocessed: true x-codetwo-clientsignature-inserted: true X-MS-Exchange-Organization-AuthMechanism: 04 X-MS-Exchange-CrossTenant-MailboxType: HOSTED X-MS-Exchange-CrossTenant-UserPrincipalName: Zf4BXs6saMh+KodsG3zgP/nB6RhXktumy5b2lKiinomIcCvVbmoS+eUoHZvbxfC4G9iRHes8XcUaCLpveFLOsS1HvcX9m6caUxSCGMwY+3A= msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-06-26T09:16:16.459Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; This is a multipart message in MIME format. ------=_NextPart_000_002F_01DD072E.90C088D0 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Teie:    12.06.2026 nr 1.2-2/53-1 Meie:   26.06.2026 nr JUR-3/3345-2 Tere Ravimiametil palub parandada eelnõus vea ja parandada seletuskiri järgnevalt: 4) paragrahvi 2 lõiget 3 täiendatakse punktidega 31 ja 32 järgmises sõnastuses: „31) ATC kood H02 – kortikosteroidid dermatoloogiliseks kasutamiseks; 32) ATC kood D011AH02 – pimekroliimus;“; Määruse § 2 lg 3 p-s 7 on juba vastav ATC rühm nimetatud. ATC kood H02 asemel peab olema D07. Seletuskirjas lehekülg 3: Punktiga 4 täiendatakse määruse nr 30 § 2 lõiget 3 punktidega 31 ja 32. Punkti 31 lisamise põhjuseks on see, et hambaarstidel on lubatud välja kirjutada ATC koodiga J02 ravimeid, mis tagab süsteemse põletikuravi. "JO2" asemel peab olema H02 (kortikosteroidid süsteemseks kasutamiseks). Lugupidamisega Andrus Varki juhataja Õigusosakond Ravimiamet 737 4140 www.ravimiamet.ee Selles e-kirjas sisalduv teave (kaasa arvatud manused) on mõeldud ametialaseks kasutamiseks ning seda võivad kasutada vaid e-kirja adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt väljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. Juhul, kui Te olete saanud käesoleva e-kirja eksituse tõttu, teavitage sellest koheselt saatjat ning kustutage e-kiri. This e-mail and any attachments transmitted may contain confidential and privileged information. If you are not the intended recipient, please notify the sender immediately by returning the e-mail and permanently deleting what you have received. Any dissemination or use of this information by a third person without permission is prohibited and may be illegal. ------=_NextPart_000_002F_01DD072E.90C088D0 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable
Teie:=E2=80=82=E2=80=82=E2=80=82=E2=80=8212.06.2026 nr 1.2-2/53-1
Meie:=E2=80=82=E2=80=82=E2=80=8226.06.2026 nr JUR-3/3345-2


Tere

Ravimiametil palub parandada eeln=C3=B5us vea ja parandada seletuskiri = j=C3=A4rgnevalt:

4) paragrahvi 2 l=C3=B5iget 3 t=C3=A4iendatakse punktidega = 31 ja 32 j=C3=A4rgmises s=C3=B5nastuses:
 
=E2=80=9E31) ATC kood H02 =E2=80=93 kortikosteroidid dermatoloogiliseks = kasutamiseks;
32) ATC kood D011AH02 =E2=80=93 pimekroliimus;=E2=80=9C;

M=C3=A4=C3=A4ruse =C2=A7 2 lg 3 p-s 7 on juba vastav ATC r=C3=BChm = nimetatud. ATC kood H02 asemel peab olema D07.

Seletuskirjas lehek=C3=BClg 3:

Punktiga 4 t=C3=A4iendatakse m=C3=A4=C3=A4ruse nr 30 =C2=A7 = 2 l=C3=B5iget 3 punktidega 31 ja 32.
Punkti 31 lisamise p=C3=B5hjuseks on see, et hambaarstidel on = lubatud v=C3=A4lja kirjutada ATC koodiga J02 ravimeid, = mis tagab s=C3=BCsteemse p=C3=B5letikuravi.

"JO2" asemel peab olema H02 (kortikosteroidid = s=C3=BCsteemseks kasutamiseks).



Lugupidamisega

Andrus Varki

juhataja

=C3=95igusosakond


Ravimiamet

737 4140

www.ravimiamet.ee


Selles = e-kirjas sisalduv teave (kaasa arvatud manused) on m=C3=B5eldud = ametialaseks kasutamiseks ning seda v=C3=B5ivad kasutada vaid e-kirja = adressaadid. E-kirjas sisalduvat teavet ei tohi ilma saatja selgelt = v=C3=A4ljendatud loata edasi saata ega mis tahes viisil kolmandatele isikutele avaldada. = Juhul, kui Te olete saanud k=C3=A4esoleva e-kirja eksituse t=C3=B5ttu, = teavitage sellest koheselt saatjat ning kustutage e-kiri. 
This e-mail and any attachments transmitted may = contain confidential and privileged information. If you are not the = intended recipient, please notify the sender immediately by = returning the e-mail and permanently deleting what you have = received. Any dissemination or use of this information by a third person without permission is = prohibited and may be illegal. 



 

------=_NextPart_000_002F_01DD072E.90C088D0--